DNA amplifications and deletions frequently contribute to the development and progression of lung cancer. To identify such novel alterations in small cell lung cancer (SCLC), we performed comparative genomic hybridization on a set of 24 SCLC cell lines, using cDNA microarrays representing B22 000 human genes (providing an average mapping resolution of o70 kb). We identified localized DNA amplifications corresponding to oncogenes known to be amplified in SCLC, including MYC (8q24), MYCN (2p24) and MYCL1 (1p34). Additional highly localized DNA amplifications suggested candidate oncogenes not previously identified as amplified in SCLC, including the antiapoptotic genes TNFRSF4 (1p36), DAD1 (14q11), BCL2L1 (20q11) and BCL2L2 (14q11). Likewise, newly discovered PCR-validated homozygous deletions suggested candidate tumor-suppressor genes, including the proapoptotic genes MAPK10 (4q21) and TNFRSF6 (10q23). To characterize the effect of DNA amplification on gene expression patterns, we performed expression profiling using the same microarray platform. Among our findings, we identified sets of genes whose expression correlated with MYC, MYCN or MYCL1 amplification, with surprisingly little overlap among gene sets. While both MYC and MYCN amplification were associated with increased and decreased expression of known MYC upregulated and downregulated targets, respectively, MYCL1 amplification was associated only with the latter. Our findings support a role of altered apoptotic balance in the pathogenesis of SCLC, and suggest that MYC family genes might affect oncogenesis through distinct sets of targets, in particular implicating the importance of transcriptional repression.
Introduction
Lung cancer is the leading cause of cancer mortality in the United States, claiming approximately 160 000 lives per year (Jemal et al., 2004) , with tobacco smoking recognized as the major cause of this disease (Shopland, 1995) . Lung cancers are classified into two major clinicopathological types, small cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC). SCLC, accounting for 15-20% of lung cancers, displays neuroendocrine features and a propensity for rapid growth and early metastasis (Travis, 2002) . With current chemotherapy regimens, the 5-year survival rate for patients with limited-and extensive-stage disease is 20 and o5%, respectively (Spira and Ettinger, 2004) . A better understanding of the molecular pathogenesis of SCLC would likely suggest strategies for earlier diagnosis and new molecular-targeted therapies.
A frequent molecular alteration in SCLC is the amplification and overexpression of the MYC family of oncogenes, MYC (c-Myc), MYCN (N-Myc) or MYCL1 (L-Myc), occurring in 18-31% of SCLCs, and more common in chemo-refractory disease (Wistuba et al., 2001) . MYC family oncoproteins are basic helix-loop-helix (bHLH) transcriptional activators that bind as heterodimers with MAX to E-box sequence motifs to activate transcription (Blackwood and Eisenman, 1991) . While early studies identified a limited number of MYC transcriptional targets involved in cell-cycle progression (Grandori and Eisenman, 1997) , more recent investigations, including microarray-based expression profiling and chromatin immunoprecipitation studies, indicate that MYC transcriptionally activates several hundred target genes that participate in diverse biological processes (Patel et al., 2004) . MYC expression also results in the transcriptional repression of many genes, although this effect is indirect, not involving binding to E-box sites (Claassen and Hann, 1999) . Although MYCN and MYCL1 also bind E-box sites (Ma et al., 1993) , comparably little is known regarding their transcriptional targets.
Other alterations frequent in SCLC include upregulation of the antiapoptotic protein BCL2, and abnormalities in the TP53 tumor-suppressor gene (TSG) (Wistuba et al., 2001) . Comparative genomic hybridization (CGH) studies have further identified frequent gains at chromosomal regions 3q26-29, 5p12-13 and 8q23-24, and losses at 3p13-14, 4q32-35, 5q32-35, 8p21-22, 10q25, 13q13-14 and 17p12-13, among others (Balsara and Testa, 2002) . However, due of the limited mapping resolution of conventional chromosome-based CGH, the underlying oncogenes and TSGs largely remain to be identified, and additional more localized aberrations likely remain to be discovered.
Here, we have used array-based CGH (aCGH) (Solinas-Toldo et al., 1997; Pinkel et al., 1998; Pollack et al., 1999; Lucito et al., 2000) to map DNA copy number alterations genome-wide at submegabase resolution in a collection of 24 SCLC cell lines. In parallel, we have profiled gene expression on the same microarray platform. We report the identification of numerous highly localized DNA amplifications and deletions that suggest candidate oncogenes and TSGs, several involved in the control of apoptosis. In addition, we describe the impact of MYC family gene amplification on gene expression patterns, for which our findings suggest that MYC, MYCN and MYCL1 amplification might affect transformation through distinct downstream targets, and in particular highlight the role of transcriptional repression by MYC family proteins in the pathogenesis of SCLC.
Results

Identification of localized DNA amplifications and homozygous deletions
To identify DNA amplifications and deletions, we performed CGH on a set of 24 SCLC cell lines using cDNA microarrays containing B22 000 different human genes, thereby providing an average mapping resolution of less than 70 kb. We observed numerous chromosomal regions of recurrent gain and loss (Supplementary Figures S1 and S2) , the spectrum of which was consistent with conventional CGH studies (Balsara and Testa, 2002) . In addition, we identified several localized high-level DNA amplifications (i.e. fluorescence ratios X3, corresponding to at least fivefold amplification (Pollack et al., 1999) ) and presumptive homozygous deletions (i.e. fluorescence ratios p0.25) (Table 1) . Altogether, we identified 22 high-level amplifications in 16 different cell lines, spanning 78-4038 kb in size (median 718 kb), and nine presumptive homozygous deletions in six cell lines, spanning 14-1102 kb (median 377 kb).
A subset of the high-level DNA amplifications corresponded to oncogenes known to be amplified in SCLC, including MYC (8q24; amplified in four cell lines), MYCN (2p24; three lines) and MYCL1 (1p34; six lines) (Supplementary Figure S3) . Additional highly localized DNA amplifications suggested candidate oncogenes not previously identified as amplified in SCLC (Table 1) , including the antiapoptotic genes TNFRSF4 (OX40; 1p36) (Kawamata et al., 1998) , DAD1 (defender against cell death 1; 14q11) (Nakashima et al., 1993) , and the BCL2 family members BCL2L1 (BCL-X L ; 20q11) (Figure 1b , e) and BCL2L2 (BCL-W; 14q11) ( Figure 1a, d ) (Cory and Adams, 2002) . Of the genes well measured by expression profiling, DAD1, BCL2L1 and BCL2L2 (Table 1 and Figure 1a , b) displayed elevated expression when amplified. In addition, BCL2 itself was found amplified within a broad amplicon at 18q21-22 (Supplementary Figure S2) , and displayed comparably elevated expression in an additional five nonamplified cell lines. We note that other genes within these amplicons also exhibited elevated expression and could contribute to pathogenic phenotypes (e.g. see Figure 1a , b). We also identified several localized presumptive homozygous deletions, suggesting new candidate TSGs (Table 1) . Those verified as homozygous deletions by PCR included the proapoptotic genes MAPK10 (JNK3; 4q21) (Yang et al., 1997) and TNFRSF6 (FAS; 10q23) (Curtin and Cotter, 2003) (Figure 1c, f) , the latter just distal to the known tumorsuppressor PTEN, which was not itself homozygously deleted (data not shown).
Expression signatures of MYC family gene amplification
Of the 24 cell lines, 13 harbored amplification of one of the MYC family genes. As MYC oncoproteins are transcriptional activators, the genes whose expression correlates with MYC family gene amplification may include the transcriptional targets and downstream effectors of MYC-mediated transformation. Using a threshold based on the Pearson correlation and the t-statistic (see Materials and methods), we identified 375 genes whose expression correlated with MYC amplification (false discovery rate, FDR ¼ 17%), of which 232 and 143 genes displayed increased and decreased expression, respectively (Figure 2a, b) . The set of 232 positively correlated genes exhibited a 5.1-fold enrichment of known MYC upregulated targets compared to the genes analyzed on the microarray (Po10 À4 , Fisher's exact test). Among the set of 143 negatively correlating genes, no significant enrichment of known MYC downregulated targets was observed.
Using the same criteria, we identified 250 genes (114 increased, 136 decreased) whose expression correlated with MYCN amplification (FDR ¼ 45%), and 49 genes (24 increased, 25 decreased) correlated with MYCL1 amplification (FDR ¼ 58%) (Figure 2a , b). The higher FDRs for these gene sets indicate less robust expression signatures compared to MYC amplification. The sets of genes positively-and negatively-correlated with MYCN amplification exhibited a significant enrichment for known MYC upregulated (2.7-fold; P ¼ 0.01) and downregulated (3.2-fold; P ¼ 0.02) targets, respectively. Notably, however, no significant enrichment was observed for the sets of MYCL1-correlated genes.
We observed a modest but significant overlap (i.e. more than expected by chance) among the genes whose expression positively-correlated with MYC and MYCN amplification (17 genes; Po10 To determine whether we could detect a smaller but significant association of the expression of known MYC targets in MYCL1-amplified samples, we also applied a different analytical approach, Gene Set Enrichment Analysis (GSEA) (Lamb et al., 2003; Mootha et al., 2003) . By considering gene sets, rather than individual genes, GSEA is more sensitive to detect subtle but significant expression patterns in microarray data. Applied here, GSEA analysis functions by 'capturing' the position of known MYC targets among the rankordered list of genes whose expression correlates with MYC family gene amplification, and then assesses whether that position is significantly higher than expected by chance. By GSEA analysis, both MYC and MYCN amplification were associated with the increased and decreased expression of known MYC upregulated and downregulated targets, respectively (Figure 3a-d) . In contrast, MYCL1 amplification was associated with the decreased expression of known MYC downregulated targets (Figure 3f ), but strikingly not with the increased expression of known MYC upregulated targets ( Figure 3e , compare with a and c). 
Discussion
A main objective of our study was to identify localized DNA amplifications and deletions in SCLC, thereby defining the location of previously unrecognized candidate oncogenes and TSGs. In our aCGH analysis of 24 SCLC cell lines, we identified 22 localized high-level amplifications, as well as nine presumptive homozygous deletions, five of which we followed up and validated by PCR. Of the candidate oncogenes and TSGs identified, many function in the control of apoptosis. Moreover, the 'direction' of DNA copy number change, that is, amplification of anti-apoptotic genes (TNFRSF4, DAD1, BCL2L1 and BCL2L2) and deletion of proapoptotic genes (MAPK10 and TNFRSF6), is for each expected to shift the apoptotic balance to favor survival Combined microarray analysis of SCLC YH Kim et al of tumor cells. Of note, all but one of these apoptotic aberrations were found in SCLC cell lines harboring amplification of a MYC family oncogene. Deregulated expression of MYC drives cell proliferation, but also strongly promotes apoptosis in many physiological contexts (Prendergast, 1999) . Therefore, there is likely strong selective pressure for cells with MYC family gene amplification to acquire (or already harbor) additional alterations to evade this apoptotic response. Indeed, MYC and BCL2 collaborate in the development of murine lymphomas (Cory et al., 1999) , and loss of expression of the proapoptotic genes CASP8, CASP10, TNFRSF10B (DR5), TNFRSF6 (FAS) and TNFSF6 (FASL) was recently reported in SCLC with MYC family gene amplification (Shivapurkar et al., 2002) . Our findings underscore the importance of altered apoptotic balance in the pathogenesis of SCLC, and, more specifically, support the potential utility of BCL2-family inhibitors (Hersey and Zhang, 2003) in its treatment.
In addition to an antiapoptotic theme emerging from the aCGH data, other biological processes were represented among candidate genes (Table 1) . Other candidate oncogenes more highly expressed when amplified included SOX4, frequently activated by retroviral insertion in murine leukemias and lymphomas (Suzuki et al., 2002) , NOL1, a proliferation-associated nucleolar antigen linked to cell transformation (Perlaky et al., 1992) , CDCA3, required for mitotic entry (Ayad et al., 2003) , and PELI2, an upstream activator of NFkB and the mitogen-activated protein (MAP) kinase pathway (Jensen and Whitehead, 2003) . Deleted candidate TSGs included WWOX, located within the common fragile site FRA16D and exhibiting tumorsuppressive activity in breast cancer (Bednarek et al., 2001) . Additional studies are required to characterize the functional role of identified genes in the development or progression of SCLC.
Expression profiling in parallel also provided an opportunity to identify expression signatures of MYC family gene amplification. We discovered a strong signature of MYC amplification, and less robust signatures of MYCN and MYCL1 amplification. We identified a modest but significant overlap between the genes correlated with MYC and MYCN amplification, consistent with a recent microarray study comparing MYC-amplified medulloblastoma and MYCN-amplified neuroblastoma cell lines (Raetz et al., 2003) . Notable, however, we observed little overlap among the genes correlated with MYC or MYCN-amplification and those correlated with MYCL1 amplification. Little is known of the transcriptional targets of MYCL1. In our study, most of the named genes whose expression positively correlated with MYCL1 amplification had known neuronal functions or expression patterns. Consonant with our findings, MYCL1 is expressed in the developing fetal brain (Hirvonen et al., 1990) .
That we observed little overlap among the signatures of MYC family gene amplification (particularly in regard to MYCL1), and no common overlap among all three of the gene sets correlated with MYC family gene amplification, was surprising. Amplification of MYC, MYCN and MYCL1 in SCLC specimens are generally mutually exclusive (Wistuba et al., 2001) , MYC family oncoproteins bind a shared E-box binding site (Ma et al., 1993) , and MYCN can functionally replace MYC in normal mouse development (Malynn et al., 2000) , all suggesting a functional redundancy of the MYC family members. Our findings suggest the possibility that different MYC family oncoproteins might affect tumorigenesis through activation or repression of distinct transcriptional targets. Alternatively, a set of common targets mediating transformation might exist but display less well-correlated expression with MYC family gene amplification in our data set.
Indeed, GSEA analysis identified a small but significant correlation of the expression of the large set of known MYC targets with the amplification of MYC family genes. Notably, for MYCL1 amplification, a significant association was found for genes whose expression was negatively correlated with known MYC downregulated targets, but not for genes whose expression was positively correlated with known MYC upregulated targets. Given the presumed functional redundancy of MYC family genes, our findings strongly implicate an importance of MYC-family mediated gene repression in the pathogenesis of SCLC. While most studies have focused on MYC's role in activating the transcription of target genes, naturally-occurring variants and directed mutations of MYC which separate its transcriptional activating and repressive functions have supported a role of gene repression in MYC-mediated transformation (Li et al., 1994; Xiao et al., 1998) , perhaps through inhibiting growth arrest or cell differentiation (Claassen and Hann, 1999) . Deregulated expression of MYC family genes has been implicated in a wide range of tumor types (Nesbit et al., 1999) . While much remains to be investigated, our findings provide additional insight into the role of MYC family genes in the pathogenesis of human cancer.
Materials and methods
Lung cancer cell lines 'NCI-H' series SCLC cell lines, established at the National Cancer Institute (Carney et al., 1985) , and 'HCC' series cell Table S1 ). Cell lines were cultured in RPMI with 5% fetal calf serum, and sub-confluent cultures were harvested separately for DNA and RNA isolation. Genomic DNA was prepared by phenol/chloroform extraction, and RNA was prepared using the Qiagen RNeasy Midi Kit. The Kolmogorov-Smirnov score (S) is the maximum (for upregulated targets) or minimum (for downregulated targets) value of the running sum. The value of S is highly positive when many MYC upregulated targets appear early in the list, and is highly negative when many MYC downregulated targets appear late in the list. The significance of S is tested by comparison to 1000 trials with randomly permuted class labels (i.e. amplified versus nonamplified); the P value is estimated as the frequency that S in the actual data is equaled or exceeded.
Array CGH and expression profiling cDNA microarrays were obtained from the Stanford Functional Genomics Facility and included 39 632 human cDNAs, representing 22 245 mapped human genes (18 446 UniGene clusters (Schuler, 1997) ), together with 3799 additional mapped ESTs not assigned UniGene IDs. We performed aCGH and expression profiling according to our published protocols (Pollack et al., 2002; Lapointe et al., 2004) . In brief, for aCGH, 4 mg of genomic DNA from each cell line was random-primer labeled with Cy5 and cohybridized to the microarray along with 4 mg of Cy3-labeled sex-matched normal leukocyte reference DNA from a single donor. For gene expression profiling, 50 mg of total RNA from each cell line and 1.5 mg of 'universal' reference mRNA (derived from 11 different established human cell lines) were differentially labeled with Cy5 and Cy3, respectively, and cohybridized to cDNA microarrays. Following overnight hybridization and washing, arrays were imaged using a GenePix 4000B scanner (Axon). Fluorescence ratios were extracted using GenePix Pro software, and the data uploaded into the Stanford Microarray Database (Gollub et al., 2003) for storage, retrieval and analysis. The complete microarray datasets are available at http://smd.stanford.edu.
Data analysis
For aCGH, background-subtracted fluorescence ratios were normalized for each array by setting the average fluorescence ratio for all array elements equal to one. Genes were considered reliably measured if the fluorescence intensity for the Cy3 reference channel was at least 1.4-fold above background. Map positions for arrayed cDNA clones were assigned using the NCBI genome assembly, accessed through the UCSC genome browser (NCBI Build 34). For genes represented by multiple arrayed cDNAs, the average fluorescence ratio was used. DNA copy number gains and losses were identified using the CLuster Along Chromosomes method (CLAC;
http://www-stat.stanford.edu/~wp57/CGH-Miner) (Wang et al., 2005) . Briefly, the CLAC algorithm builds a hierarchical cluster-style tree along each chromosome, such that neighboring genes with positive and negative ratios are separated into different clusters. Gains and losses are then called significant based on the height and width of clusters, and a FDR is estimated by comparison to normal-normal hybridization data. We defined high-level DNA amplifications and presumptive homozygous deletions as contiguous regions identified by CLAC with more than 40% of genes, and a minimum of three genes, displaying fluorescence ratios X3 or p0.25, respectively. For expression profiling, fluorescence ratios were normalized for each array, and then well-measured genes (fluorescence intensities for the Cy5 or Cy3 channel at least 1.5-fold above background) were subsequently 'meancentered' (i.e. reported for each gene relative to the mean ratio across all samples, rather than relative to the arbitrary universal reference). Colorimetric representations of fluorescence ratios were rendered using TreeView software (http:// rana.lbl.gov/EisenSoftware.htm). We defined genes whose expression was associated with amplification of MYC, MYCN or MYCL1 as those meeting the following three criteria: (1) gene expression correlated (Pearson correlation |R|X0.65) with amplification considered as a binary variable; (2) gene expression significantly altered in samples with amplification (two-tailed Student's t-test, Po0.05); and (3) X2-fold difference in average expression between amplified and nonamplified samples. For this analysis, MYC, MYCN and MYCL1-amplified sample sets were each separately compared to the set of 10 remaining samples with no MYC gene family amplification, using the common set of 13 944 genes (including 9569 named genes) having well-measured ratios in more than 50% of each of these four sample subsets. To estimate a FDR (i.e. the fraction of genes falsely called significant) (Tusher et al., 2001) , we compared our results to those obtained from 1000 trials performed on the same data in which class labels (i.e. amplified versus nonamplified) were first randomly permuted. Known MYC (c-myc) targets were identified from the Myc Target Gene Database (Zeller et al., 2003) (http://www.myccancergene.org/site/mycTargetDB.asp). GSEA, based on the Kolmogorov-Smirnov statistic, was performed exactly as described (Lamb et al., 2003) , using 1000 trials with randomly permuted class labels to estimate a P-value.
Fluorescence in situ hybridization Interphase fluorescence in situ hybridization (FISH) was performed using a Spectrum-Green labeled bacterial artificial chromosome probe corresponding to the 14q11 locus (RP11-81F9, Children's Hospital Oakland Research Institute) and a Spectrum-Orange labeled chromosome 14 telomere probe (TelVysion 14q; Vysis). FISH was performed exactly according to the Vysis labeling and hybridization protocols, and images were captured using an Olympus BX51 microscope and Applied Imaging Cytovision 3.0 software.
PCR analysis
To validate homozygous deletions, we used gene-specific primer-pairs to PCR amplify genomic DNA from cell lines. Primer-pairs for genes flanking the regions of presumptive homozygous deletion, and designed to have a distinguishable fragment size, were included in a subset of the PCR reactions as internal controls. PCR was performed on an Applied Biosystems GeneAmp 9700 instrument, using 100 ng DNA template, 1 Â PCR Gold buffer (Applied Biosystems), 160 mM dNTPs, 1.5 mM MgCl, 20 pmol each individual primer (Supplementary Table S2) , and 1 U of AmpliTaq Gold (Applied Biosystems) in a 25 ml reaction for 35 cycles (941C 30 s; annealing temperature (see Supplementary Table S2 ) 30 s; 721C 30 s), followed by gel electrophoresis on a 1.8 % TAE agarose gel, and visualization using an Alpha Innotech imaging system.
Reverse transcription (RT)-PCR analysis
To characterize the expression of transcripts from the BCL2L1 locus, we performed RT-PCR using a primer-pair that distinguishes the antiapoptotic BCL-X L and proapoptotic BCL-X S alternative transcripts based on the size of the amplification product (Taylor et al., 1999) . Reverse transcription and PCR were separately performed using primers TTGGACAATGGACTGGTTGA (forward) and AGTG GATGGTCAGTGTCTGGT (reverse). Reverse transcription was carried out using the SuperScript First-Strand Synthesis System (Invitrogen), according to manufacturer's protocol. PCR was performed as above using 1/10th the RT reaction for template in a 25 ml reaction for 35 cycles (941C 45 s, 601C 1 min, 721C 5 min).
Abbreviations SCLC, small cell lung cancer; TSG, tumor suppressor gene; aCGH, array-based comparative genomic hybridization; FDR, false discovery rate; GSEA, gene set enrichment analysis.
